Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids

• Asıl Yazarlar: Jie Jian (Yazar), Mei-Tong Nie (Yazar), Baoyu Xiang (Yazar), Hui Qian (Yazar), Chuan Yin (Yazar), Xin Zhang (Yazar), Menghui Zhang (Yazar), Xuan Zhu (Yazar), Wei-Fen Xie (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2022-04-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Non-alcoholic steatohepatitis (NASH) is the progressive stage of non-alcoholic fatty liver disease (NAFLD). The non-absorbable antibiotic rifaximin has been used for treatment of irritable bowel syndrome, traveling diarrhea, and hepatic encephalopathy, but the efficacy of rifaximin in NASH patients...